That said, Recursion doesn't have a single therapy on the market yet. Over the past four years, the company has made little ...

Recursion Pharmaceuticals recently reported positive phase 2 results for REC-994, a potential treatment for symptomatic cerebral cavernous malformation, a disease caused by the abnormal formation ...

Success for just one of Recursion's phase 2 programs could enable the stock to double within five years. However, the odds of success for phase 2 candidates aren't good. Risk-averse investors ...

After the market close on Wednesday, Recursion said it intends to offer and sell $200 million worth of its common stock in an underwritten public offering. All of the shares are being offered by ...

Recursion has more expressive power than iterative looping constructs. I say this because a while loop is equivalent to a tail recursive function and recursive functions need not be tail recursive.

Recursion Pharmaceuticals Inc RXRX shares are trading lower. The company on Tuesday announced Phase 2 data for an investigational treatment for symptomatic Cerebral Cavernous Malformation (CCM ...

Is Recursion Still Being Made? We haven’t heard much about Recursion since the initial announcement from Netflix. However, it’s allegedly still in the works with Netflix, Rhimes, and Reeves.

Recursion Pharmaceuticals (NASDAQ: RXRX) is a clinical stage company that mixes healthcare with technology and artificial intelligence (AI). Its drug discovery platform, Recursion OS, is the key ...